People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fluent, Inc. | — | Other | Series D+ | $264.9M | $97.2M | 2015 |
| ChromaDex Corp. | — | Biotechnology | Series B | $110.4M | $46.9M | 2022 |
ROBERT N FRIED at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ROBERT N FRIED on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Rubin | 2 | 7 |
| MICHAEL BRAUSER | 2 | 6 |
| Robert Fried | 2 | 2 |
| Steven D. Rubin | 1 | 9 |
| Mark Friedman | 1 | 8 |
| Barry Honig | 1 | 6 |
| Jeff Baxter | 1 | 4 |
| James Reilly | 1 | 4 |
| Peter Benz | 1 | 4 |
| David Graff | 1 | 3 |
| Glenn L. Halpryn | 1 | 3 |
| Daniel Brauser | 1 | 3 |
| Stephen Block | 1 | 3 |
| Thomas Varvaro | 1 | 3 |
| Derek Dubner | 1 | 2 |
| Thomas L Varvaro | 1 | 2 |
| Mark S. Germain | 1 | 2 |
| Thomas C. Varvaro | 1 | 2 |
| Frank Jaksch | 1 | 2 |
| Frank L Jaksch | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.